Cor Vasa 2012, 54(3-4):e97-e103 | DOI: 10.1016/j.crvasa.2012.01.012

Clinical monitoring of the antithrombotic treatment

Jan Vojáček
I. interní kardioangiologická klinika, Lékařská fakulta Univerzity Karlovy v Hradci Králové a Fakultní nemocnice Hradec Králové, Hradec Králové, Česká republika

Keywords: Antikoagulační léčba; Protidestičková léčba

Received: January 2, 2012; Revised: January 23, 2012; Accepted: January 24, 2012; Published: March 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vojáček J. Clinical monitoring of the antithrombotic treatment. Cor Vasa. 2012;54(3-4):e97-103. doi: 10.1016/j.crvasa.2012.01.012.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Vojáček J. The results of the RE-LY study promise more effective, safer and easier prevention of embolic complications in patients with non-valvular atrial fibrillation. Vnitř Lék 2009;11:1085-8.
    2. Granger CB, Hirsch J, Califf RM, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation 1996;93:870-8. Go to original source... Go to PubMed...
    3. Hill JD, Dontigny L, de Leval M, et al. A simple method of heparin management during prolonged extracorporeal circulation. Ann Thorac Surg 1974;17:129-34. Go to original source...
    4. Mattox KC, Guinn GA, Rubio PA, et al. Use of the activated coagulation time in intraoperative heparin reversal for cardiopulmonary operations. Ann Thorac Surg 1975; 19:634-8. Go to original source...
    5. Hattersley PG. Activated coagulation time of whole blood. JAMA 1966;196:436-40. Go to original source...
    6. Ferguson JJ, Dougherty KG, Gaos CM, et al. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994;23:1061-5. Go to original source...
    7. Ferguson JJ. All ACTs are not created equal [editorial]. Tex Heart Inst J 1992;19:1-3.
    8. Marmur JD, Poludasu S, Feit A, et al. Activated clotting time (ACT)-guided intravenous dalteparin dosing during percutaneous coronary intervention. J Invas Cardiol 2008;20:323-7.
    9. Bertrand OF, Rodés-Cabau J, Rinfret S, et al. Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy. Am J Cardiol 2009;104:1235-40. Go to original source... Go to PubMed...
    10. Capuano C, Sesana M, Leonzi O, Cuccia CJ. Safety and efficacy of low-dose unfractionated heparin during percutaneous coronary revascularisation and the relationship between activated clotting time and haemorrhagic or ischaemic complications: our results. Cardiovasc Med 2006;7:866-71. Go to original source... Go to PubMed...
    11. Fuchs S, Kornowski R, Teplitsky I, et al. Major bleeding complicating contemporary primary percutaneous coronary interventions-incidence, predictors, and prognostic implications. Cardiovasc Revasc Med 2009;10:88-93. Go to original source... Go to PubMed...
    12. van Ryn J, Stangier JJ, Haertter S, et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1116-27. Go to original source... Go to PubMed...
    13. Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med 2011;49:761-72. Go to original source... Go to PubMed...
    14. Calatzis A, Peetz D, Haas S, et al. Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors. Am J Clin Pathol 2008; 130:446-54. Go to original source... Go to PubMed...
    15. Gurbel PA, Tantry US. The relationship of platelet reactivity to the occurrence of post- stenting ischemic events: emergence of a new cardiovascular risk factor. Rev Cardiovasc Med 2006;7(Suppl 4):387-95.
    16. Bonello L, Tantry US, Marcucci R, et al. Working Group on High On-Treatment Platelet Reactivity, Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919-33. Go to original source... Go to PubMed...
    17. Sibbing D, Byrne RA, Bernlochner I, Kastrati A. High platelet reactivity and clinical outcome - fact and fiction. Thromb Haemost 2011;106:191-202. Go to original source... Go to PubMed...
    18. Bonello L, Pansieri M, Mancini J, et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 2011;58:467-73. Go to original source... Go to PubMed...
    19. Lordkipanidzé M, Pharand C, Nguyen TA, et al. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. Eur Heart J 2008;29:2877-85. Go to original source... Go to PubMed...
    20. Weber AA, Adamzik M, Bachmann HS, et al; for the "Interdisciplinary Study Group - Clinical Pharmacology of Haemostasis". Methods to evaluate the pharmacology of oral antiplatelet drugs. Herz 2008; 33:287-96. Go to original source... Go to PubMed...
    21. Gurbel PA, Bliden KP, DiChiara J, et al. Evaluation of dose-related effects of aspirin on platelet function: Results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007;115:3156-64. Go to original source... Go to PubMed...
    22. Angiolillo DJ, Suryadevara S, Capranzano P, Zenni MZ, Guzman LA, Bass TA. Antiplatelet drug response variability and the role of platelet function testing: a practical guide for interventional cardiologists. Catheter Cardiovasc Interv 2009;73:1-14. Go to original source... Go to PubMed...
    23. Hobikoglu GF, Norgaz T, Aksu H, et al. High frequency of aspirin resistance in patients with acute coronary syndrome. Tohoku J Exp Med 2005;207:59-64. Go to original source... Go to PubMed...
    24. Calabrò P, Golia E, Yeh ET. CRP and the risk of atherosclerotic events. Semin Immunopathol 2009; 31:79-94. Go to original source... Go to PubMed...
    25. Futterman LG, Lemberg L. High-sensitivity C-reactive protein is the most effective prognostic measurement of acute coronary events. Am J Crit Care 2002;11:482-6. Go to original source...
    26. Vojáček J, Ševčíková H, Ševčík R, et al. Increased platelet residual activity in patients treated with acetosalicylic acid is associated with increased tissue factor and decreased tissue factor pathway inhibitor plasma level. Int J Cardiol 2011;146:479-81. Go to original source... Go to PubMed...
    27. Ševčíková H, Vojáček J, Bis J, et al. Good Short-Term but not Long-Term Reproducibility of the Antiplatelet Efficacy Laboratory Assessment. Clin Appl Thromb Hemost 2012;18:174-80. Go to original source... Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes